Hernando Jerez, Asunción
Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. [artículo] - Journal of acquired immune deficiency syndromes (1999), 2014 - 65(1):82-6.
Formato Vancouver:
Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J et al; GESIDA 3703.FIPSE 36466503-N5 NEAT Study Group. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):82-6.
PMID: 24419065
Contiene 21 referencias
This study assesses the incidence of hepatocellular carcinoma (HCC) in a prospective cohort of HIV-infected patients, the majority receiving antiretroviral therapy, with liver cirrhosis from different etiologies, enrolled between 2004 and 2005 with median follow-up of 5 years. We followed 371 patients, 25.6% with decompensated cirrhosis at baseline. The incidence rate of HCC was 6.72 per 1000 person-years [95% confidence interval (CI): 2.6 to 10.9]. There was a trend toward a higher cumulative probability of developing HCC at 6 years of follow-up (considering death and liver transplant as competing risks) in patients with decompensated versus compensated cirrhosis at baseline (6% vs. 2%, P < 0.06).
Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. [artículo] - Journal of acquired immune deficiency syndromes (1999), 2014 - 65(1):82-6.
Formato Vancouver:
Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J et al; GESIDA 3703.FIPSE 36466503-N5 NEAT Study Group. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):82-6.
PMID: 24419065
Contiene 21 referencias
This study assesses the incidence of hepatocellular carcinoma (HCC) in a prospective cohort of HIV-infected patients, the majority receiving antiretroviral therapy, with liver cirrhosis from different etiologies, enrolled between 2004 and 2005 with median follow-up of 5 years. We followed 371 patients, 25.6% with decompensated cirrhosis at baseline. The incidence rate of HCC was 6.72 per 1000 person-years [95% confidence interval (CI): 2.6 to 10.9]. There was a trend toward a higher cumulative probability of developing HCC at 6 years of follow-up (considering death and liver transplant as competing risks) in patients with decompensated versus compensated cirrhosis at baseline (6% vs. 2%, P < 0.06).
